In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.

[1]  S. H. Alves,et al.  In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. , 2011, Mycoses.

[2]  G. Alangaden,et al.  Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. , 2008, Diagnostic microbiology and infectious disease.

[3]  T. Walsh,et al.  Isobolographic Analysis of Pharmacodynamic Interactions between Antifungal Agents and Ciprofloxacin against Candida albicans and Aspergillus fumigatus , 2008, Antimicrobial Agents and Chemotherapy.

[4]  S. Córdoba,et al.  In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. , 2008, International journal of antimicrobial agents.

[5]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[6]  E. Anaissie,et al.  Fusarium Infections in Immunocompromised Patients , 2007, Clinical Microbiology Reviews.

[7]  D. Geiser,et al.  Phylogenetic Diversity and Microsphere Array-Based Genotyping of Human Pathogenic Fusaria, Including Isolates from the Multistate Contact Lens-Associated U.S. Keratitis Outbreaks of 2005 and 2006 , 2007, Journal of Clinical Microbiology.

[8]  J. Graybill,et al.  Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Ghannoum,et al.  Combination Treatment of Invasive Fungal Infections , 2005, Clinical Microbiology Reviews.

[10]  M. Cuenca‐Estrella.  Combinations of antifungal agents in therapy--what value are they? , 2004, The Journal of antimicrobial chemotherapy.

[11]  E. Anaissie,et al.  Fusarium infection in hematopoietic stem cell transplant recipients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  E. Anaissie,et al.  Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Talbert,et al.  Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. , 2002, Journal of medical microbiology.

[14]  A. Rodrigues,et al.  Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. , 2000, Journal of medical microbiology.

[15]  J. Guarro,et al.  In Vitro and In Vivo Experimental Activities of Antifungal Agents against Fusarium solani , 1999, Antimicrobial Agents and Chemotherapy.

[16]  A. Lewin,et al.  Inhibition of RNA Synthesis as a Therapeutic Strategy against Aspergillus and Fusarium: Demonstration of In Vitro Synergy between Rifabutin and Amphotericin B , 1998, Antimicrobial Agents and Chemotherapy.

[17]  C. Clancy,et al.  The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. , 1998, The Journal of antimicrobial chemotherapy.

[18]  M. Hirschfeld,et al.  Interactions between amphotericin B and nitroimidazoles against Candida albicans , 1997, Mycoses.

[19]  E. Anaissie,et al.  Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. , 1997, Blood.

[20]  N. Chin,et al.  In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans , 1997, Antimicrobial agents and chemotherapy.

[21]  J. Guarro,et al.  In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. , 1997, The Journal of antimicrobial chemotherapy.

[22]  C. Kunin.  Antimicrobial activity of rifabutin. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  E. Scott,et al.  Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro , 1995, Antimicrobial agents and chemotherapy.

[24]  L. Peterson,et al.  In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp , 1984, Antimicrobial Agents and Chemotherapy.

[25]  G. Medoff.  Antifungal action of rifampin. , 1983, Reviews of infectious diseases.

[26]  J. Edwards,et al.  Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans , 1981, Antimicrobial Agents and Chemotherapy.

[27]  D. Henderson,et al.  Combined effect of amphotericin B and rifampin on Candida species , 1980, Antimicrobial Agents and Chemotherapy.

[28]  G. Stern.  In vitro antibiotic synergism against ocular fungal isolates. , 1978, American journal of ophthalmology.

[29]  G. Medoff,et al.  Antimicrobial Susceptibility Testing of Six Clinical Isolates of Aspergillus , 1976, Antimicrobial Agents and Chemotherapy.

[30]  D. Schlessinger,et al.  Effects of Rifamycin Derivatives, Alone and in Combination with Amphotericin B, Against Histoplasma capsulatum , 1974, Antimicrobial Agents and Chemotherapy.